| http://dbpedia.org/ontology/abstract
|
ナテグリニド は、味の素製薬株式会社により創製された経口糖尿病薬のひとつ。日本ではファステックとして味の素製薬製造・第一三共販売、スターシスとしてアステラス製薬より販売されている。海外ではStarlixとしてスイスの製薬企業ノバルティスにより販売されている。 ナテグリニドはミチグリニド、レパグリニドなどと共にグリニド系と呼ばれる。2型糖尿病患者でのグリニド系経口血糖降下薬の嚆矢である。
, Nateglinide (nella fase sperimentale conos … Nateglinide (nella fase sperimentale conosciuta con la sigla AY4166) è un composto, derivato della D-fenilalanina, appartenente alla famiglia delle megletinidi, utilizzato come farmaco ipoglicemizzante orale, a breve durata d'azione, per il trattamento del diabete mellito di tipo 2. Nateglinide è stata sviluppata da una società di ricerche giapponese, la Ajinomoto, ed i diritti sono stati successivamente venduti alla società farmaceutica svizzera Novartis.la società farmaceutica svizzera Novartis.
, Nateglinide (INN, trade name Starlix) is a … Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.ide class of blood glucose-lowering drugs.
, ناتيغلينيد (بالإنجليزية: Nateglinide) هو دواء يُستعمل في علاج:
* سكري الشبان الناضجين النوع الثاني
, Nateglinida é um fármaco da classe dos hip … Nateglinida é um fármaco da classe dos hipoglicemiantes usados via oral, secretagogo de insulina. Derivado da D-fenilalanina, promove redução do nível de glicose na circulação sanguínea logo após as refeições. É utilizada em pacientes portadores de diabetes mellitus tipo 2. De acordo com o Prontuário Terapêutico Infarmed a droga não deve ser usada isoladamente, ou seja, em monoterapia. Em relação a outros fármacos hipoglicemiantes orais, promove uma rápida secreção de insulina, todavia menos duradoura. Geralmente é administrada de 1 a 10 minutos antes das refeições numa dose de 120 mg.s antes das refeições numa dose de 120 mg.
, Nateglinide is een geneesmiddel voor de be … Nateglinide is een geneesmiddel voor de behandeling van diabetes mellitus type 2. Het stimuleert de productie van lichaamseigen insuline en verlaagt de glucosespiegel in het bloed. Het moet gebruikt worden in combinatie met metformine. Nateglinide is een derivaat van het aminozuur D-fenylalanine; een andere chemische naam voor de stof is (-)-N-(trans-4-isopropylcyclohexaancarbonyl)-D-fenylalanine. Het is een wit poeder, dat oplosbaar is in methanol, ethanol of chloroform maar bijna onoplosbaar is in water. Het is een polymorfe stof waarvan verschillende kristalstructuren bestaan die ook een verschillend smeltpunt hebben. Het middel werd ontwikkeld door het Japanse bedrijf Ajinomoto. In de Verenigde Staten en Europa (o.m. ook in Nederland) wordt het verkocht door Novartis onder de merknaam Starlix, in de vorm van tabletten voor oraal gebruik met 60 of 120 mg nateglinide.raal gebruik met 60 of 120 mg nateglinide.
, Nateglinida (INN, Starlix®) es un agente antidiabético para el tratamiento de diabetes de tipo 2 desarrollado por la empresa suiza Novartis. Pertenece a la clase de las meglitinidas de los fármacos hipoglicemiantes.
|
| http://dbpedia.org/ontology/alternativeName
|
Starlix
|
| http://dbpedia.org/ontology/casNumber
|
105816-04-4
|
| http://dbpedia.org/ontology/chEBI
|
31897
|
| http://dbpedia.org/ontology/chEMBL
|
286559
|
| http://dbpedia.org/ontology/drugbank
|
DB00731
|
| http://dbpedia.org/ontology/fdaUniiCode
|
41X3PWK4O2
|
| http://dbpedia.org/ontology/kegg
|
D01111
|
| http://dbpedia.org/ontology/medlinePlus
|
a699057
|
| http://dbpedia.org/ontology/pubchem
|
60026
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Nateglinide.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.starlix.com/index.jsp +
, https://web.archive.org/web/20090302224002/http:/www.starlix.com/info/about/howitworks.jsp +
|
| http://dbpedia.org/ontology/wikiPageID
|
5426410
|
| http://dbpedia.org/ontology/wikiPageLength
|
4319
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1122994490
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Drug +
, http://dbpedia.org/resource/Adenosine_triphosphate +
, http://dbpedia.org/resource/Category:Meglitinides +
, http://dbpedia.org/resource/Voltage-gated_calcium_channels +
, http://dbpedia.org/resource/Category:Cyclohexanes +
, http://dbpedia.org/resource/Pancreas +
, http://dbpedia.org/resource/Potassium_channels +
, http://dbpedia.org/resource/Meglitinide +
, http://dbpedia.org/resource/Category:Potassium_channel_blockers +
, http://dbpedia.org/resource/Novartis +
, http://dbpedia.org/resource/Hypersensitivity +
, http://dbpedia.org/resource/Diabetic_ketoacidosis +
, http://dbpedia.org/resource/Category:Isopropyl_compounds +
, http://dbpedia.org/resource/Repaglinide +
, http://dbpedia.org/resource/Novo_Nordisk +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Ajinomoto +
, http://dbpedia.org/resource/Type_2_diabetes +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Beta_cells +
, http://dbpedia.org/resource/Insulin +
|
| http://dbpedia.org/property/atcPrefix
|
A10
|
| http://dbpedia.org/property/atcSuffix
|
BX03
|
| http://dbpedia.org/property/c
|
19
|
| http://dbpedia.org/property/casNumber
|
105816
|
| http://dbpedia.org/property/chebi
|
31897
|
| http://dbpedia.org/property/chembl
|
286559
|
| http://dbpedia.org/property/chemspiderid
|
10482084
|
| http://dbpedia.org/property/drugbank
|
DB00731
|
| http://dbpedia.org/property/eliminationHalfLife
|
5400.0
|
| http://dbpedia.org/property/h
|
27
|
| http://dbpedia.org/property/iupacName
|
-2
|
| http://dbpedia.org/property/iupharLigand
|
6833
|
| http://dbpedia.org/property/kegg
|
D01111
|
| http://dbpedia.org/property/legalUk
|
POM
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/licenceUs
|
Nateglinide
|
| http://dbpedia.org/property/medlineplus
|
a699057
|
| http://dbpedia.org/property/n
|
1
|
| http://dbpedia.org/property/o
|
3
|
| http://dbpedia.org/property/proteinBound
|
98.0
|
| http://dbpedia.org/property/pubchem
|
60026
|
| http://dbpedia.org/property/routesOfAdministration
|
Oral
|
| http://dbpedia.org/property/smiles
|
O=C[C@H]2CC[C@@H]CC
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
OELFLUMRDSZNSF-BRWVUGGUSA-N
|
| http://dbpedia.org/property/tradename
|
Starlix
|
| http://dbpedia.org/property/unii
|
41
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
462258838
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Stdinchicite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Ion_channel_modulators +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Oral_hypoglycemics +
, http://dbpedia.org/resource/Template:Ebicite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Isopropyl_compounds +
, http://dbpedia.org/resource/Category:Potassium_channel_blockers +
, http://dbpedia.org/resource/Category:Cyclohexanes +
, http://dbpedia.org/resource/Category:Meglitinides +
, http://dbpedia.org/resource/Category:Carboxamides +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Nateglinide?oldid=1122994490&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Nateglinide.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Nateglinide +
|
| owl:sameAs |
http://yago-knowledge.org/resource/Nateglinide +
, http://vi.dbpedia.org/resource/Nateglinide +
, http://ja.dbpedia.org/resource/%E3%83%8A%E3%83%86%E3%82%B0%E3%83%AA%E3%83%8B%E3%83%89 +
, http://ro.dbpedia.org/resource/Nateglinid%C4%83 +
, http://cy.dbpedia.org/resource/Nateglinid +
, https://global.dbpedia.org/id/28fTi +
, http://www.wikidata.org/entity/Q2254797 +
, http://rdf.freebase.com/ns/m.0dlcpz +
, http://sr.dbpedia.org/resource/Nateglinid +
, http://pt.dbpedia.org/resource/Nateglinida +
, http://dbpedia.org/resource/Nateglinide +
, http://ar.dbpedia.org/resource/%D9%86%D8%A7%D8%AA%D9%8A%D8%BA%D9%84%D9%8A%D9%86%D9%8A%D8%AF +
, http://www.wikidata.org/entity/Q106029464 +
, http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/443871 +
, http://sh.dbpedia.org/resource/Nateglinid +
, http://it.dbpedia.org/resource/Nateglinide +
, http://es.dbpedia.org/resource/Nateglinida +
, http://nl.dbpedia.org/resource/Nateglinide +
, http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00731 +
|
| rdf:type |
http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://umbel.org/umbel/rc/DrugProduct +
, http://dbpedia.org/class/yago/WikicatAmides +
, http://dbpedia.org/class/yago/Amide114724264 +
|
| rdfs:comment |
Nateglinide (INN, trade name Starlix) is a … Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.ide class of blood glucose-lowering drugs.
, ナテグリニド は、味の素製薬株式会社により創製された経口糖尿病薬のひとつ。日本ではファステックとして味の素製薬製造・第一三共販売、スターシスとしてアステラス製薬より販売されている。海外ではStarlixとしてスイスの製薬企業ノバルティスにより販売されている。 ナテグリニドはミチグリニド、レパグリニドなどと共にグリニド系と呼ばれる。2型糖尿病患者でのグリニド系経口血糖降下薬の嚆矢である。
, Nateglinide (nella fase sperimentale conos … Nateglinide (nella fase sperimentale conosciuta con la sigla AY4166) è un composto, derivato della D-fenilalanina, appartenente alla famiglia delle megletinidi, utilizzato come farmaco ipoglicemizzante orale, a breve durata d'azione, per il trattamento del diabete mellito di tipo 2. Nateglinide è stata sviluppata da una società di ricerche giapponese, la Ajinomoto, ed i diritti sono stati successivamente venduti alla società farmaceutica svizzera Novartis.la società farmaceutica svizzera Novartis.
, Nateglinida é um fármaco da classe dos hip … Nateglinida é um fármaco da classe dos hipoglicemiantes usados via oral, secretagogo de insulina. Derivado da D-fenilalanina, promove redução do nível de glicose na circulação sanguínea logo após as refeições. É utilizada em pacientes portadores de diabetes mellitus tipo 2. De acordo com o Prontuário Terapêutico Infarmed a droga não deve ser usada isoladamente, ou seja, em monoterapia. Em relação a outros fármacos hipoglicemiantes orais, promove uma rápida secreção de insulina, todavia menos duradoura. Geralmente é administrada de 1 a 10 minutos antes das refeições numa dose de 120 mg.s antes das refeições numa dose de 120 mg.
, Nateglinide is een geneesmiddel voor de be … Nateglinide is een geneesmiddel voor de behandeling van diabetes mellitus type 2. Het stimuleert de productie van lichaamseigen insuline en verlaagt de glucosespiegel in het bloed. Het moet gebruikt worden in combinatie met metformine. Het middel werd ontwikkeld door het Japanse bedrijf Ajinomoto. In de Verenigde Staten en Europa (o.m. ook in Nederland) wordt het verkocht door Novartis onder de merknaam Starlix, in de vorm van tabletten voor oraal gebruik met 60 of 120 mg nateglinide.raal gebruik met 60 of 120 mg nateglinide.
, Nateglinida (INN, Starlix®) es un agente antidiabético para el tratamiento de diabetes de tipo 2 desarrollado por la empresa suiza Novartis. Pertenece a la clase de las meglitinidas de los fármacos hipoglicemiantes.
, ناتيغلينيد (بالإنجليزية: Nateglinide) هو دواء يُستعمل في علاج:
* سكري الشبان الناضجين النوع الثاني
|
| rdfs:label |
ناتيغلينيد
, ナテグリニド
, Nateglinida
, Nateglinide
|
